We showed that JNJ-165 significantly and synergistically increased TKIs oncotoxicity both in CML cell lines with p53 mutant and primary CML cells with BCR/ABL-positive, while the combination was not significant toxic for MNCs from BCR/ABL-negative CML patient. Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.